The Oncology Institute Inc
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as education… Read more
The Oncology Institute Inc (TOIIW) - Net Assets
Latest net assets as of September 2025: $-12.27 Million USD
Based on the latest financial reports, The Oncology Institute Inc (TOIIW) has net assets worth $-12.27 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($163.62 Million) and total liabilities ($175.89 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-12.27 Million |
| % of Total Assets | -7.5% |
| Annual Growth Rate | -38.91% |
| 5-Year Change | -87.23% |
| 10-Year Change | N/A |
| Growth Volatility | 129.64 |
The Oncology Institute Inc - Net Assets Trend (2019–2024)
This chart illustrates how The Oncology Institute Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for The Oncology Institute Inc (2019–2024)
The table below shows the annual net assets of The Oncology Institute Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.59 Million | -93.71% |
| 2023-12-31 | $57.02 Million | -53.70% |
| 2022-12-31 | $123.17 Million | +18.26% |
| 2021-12-31 | $104.16 Million | +270.66% |
| 2020-12-31 | $28.10 Million | -33.45% |
| 2019-12-31 | $42.22 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to The Oncology Institute Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20479797700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00K | 0.22% |
| Other Components | $214.39 Million | 5973.64% |
| Total Equity | $3.59 Million | 100.00% |
The Oncology Institute Inc Competitors by Market Cap
The table below lists competitors of The Oncology Institute Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Palram
TA:PLRM
|
$3.75 Million |
|
PT Carsurin Tbk
JK:CRSN
|
$3.75 Million |
|
Fertilizantes Heringer S.A
SA:FHER3
|
$3.75 Million |
|
BigBen Interactive
PA:BIG
|
$3.75 Million |
|
Aspen Group Inc
OTCQB:ASPU
|
$3.75 Million |
|
Renforth Resources Inc
PINK:RFHRF
|
$3.75 Million |
|
Dune Acquisition Corporation II Warrants
NASDAQ:IPODW
|
$3.75 Million |
|
Herbal Dispatch Inc.
F:HA9
|
$3.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in The Oncology Institute Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 57,025,000 to 3,589,000, a change of -53,436,000 (-93.7%).
- Net loss of 64,663,000 reduced equity.
- Other factors increased equity by 11,227,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-64.66 Million | -1801.7% |
| Other Changes | $11.23 Million | +312.82% |
| Total Change | $- | -93.71% |
Book Value vs Market Value Analysis
This analysis compares The Oncology Institute Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.98x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.07x to 0.98x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.66 | $0.05 | x |
| 2020-12-31 | $0.48 | $0.05 | x |
| 2021-12-31 | $1.57 | $0.05 | x |
| 2022-12-31 | $1.53 | $0.05 | x |
| 2023-12-31 | $0.77 | $0.05 | x |
| 2024-12-31 | $0.05 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently The Oncology Institute Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1801.70%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16.44%
- • Asset Turnover: 2.28x
- • Equity Multiplier: 48.12x
- Recent ROE (-1801.70%) is below the historical average (-336.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -9.52% | -2.59% | 2.61x | 1.41x | $-8.24 Million |
| 2020 | -50.96% | -7.64% | 2.85x | 2.34x | $-17.13 Million |
| 2021 | -10.49% | -5.38% | 1.00x | 1.95x | $-21.34 Million |
| 2022 | 0.12% | 0.06% | 0.96x | 2.12x | $-12.17 Million |
| 2023 | -145.67% | -25.62% | 1.55x | 3.67x | $-88.77 Million |
| 2024 | -1801.70% | -16.44% | 2.28x | 48.12x | $-65.02 Million |
Industry Comparison
This section compares The Oncology Institute Inc's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| The Oncology Institute Inc (TOIIW) | $-12.27 Million | -9.52% | N/A | $3.75 Million |
| Abcam plc (ABCZF) | $726.90 Million | -1.17% | 0.45x | $5.00 Billion |
| Able View Global Inc. Warrant (ABLVW) | $11.42 Million | 85.41% | 3.81x | $277.93K |
| Above Food Ingredients Inc. Warrants (ABVEW) | $199.86 Million | -2.89% | 0.00x | $6.25 Million |
| Adamas Trust, Inc. (ADAMG) | $2.43 Billion | 7.94% | 1.33x | $2.09 Billion |
| ADS-TEC ENERGY PLC Warrant (ADSEW) | $33.92 Million | -162.39% | 2.67x | $10.06 Million |
| Alliance Entertainment Holding Corporation Warrants (AENTW) | $52.92 Million | 10.13% | 4.23x | $2.29 Million |
| Forafric Global PLC Warrants (AFRIW) | $5.32 Million | -457.58% | 45.29x | $2.67 Million |
| Centurion Acquisition Corp. Warrant (ALFUW) | $282.84 Million | 1.97% | 0.05x | $4.81 Million |
| Alliance Trust PLC (ALITF) | $4.04 Billion | 10.04% | 0.29x | $112.87K |
| Alvotech Warrant (ALVOW) | $-564.42 Million | 0.00% | 0.00x | $35.01 Million |